Pilatus Biosciences (the “Company”), a biotechnology company focused on d shaping the future of cancer treatment through trailblazing First-in-class biologics focusing on metabolic checkpoints, today announced that the Company will present new preclinical data of its anti-CD36 antibody program, PLT012, at the upcoming Society for Immunotherapy of Cancer’s 38^th Annual Meeting (SITC 2023). The data will be shared in a poster presentation entitled “PLT012, a monoclonal antibody targeting CD36, unleashes anti-tumor immunity via metabolic reprogramming in tumor microenvironment”, on November 3^rd, 2023 (Abstract #1401)

Details of the poster presentation are as follows:

Full text of the abstracts will be released on the SITC website at 8:00 a.m. ET on the same day (SITC link), and the posters will be available on the Company's website(Pilatus link).

‍

About CD36 and PLT012

CD36, a fatty acid transporter, has been reported to be up-regulated in both malignant cells and tumor-associated immune cells, including regulatory T cells, tumor-associated macrophages and CD8+ T cells, to adjust the metabolic preference, which allows the cells to adapt in the lipid-enriched tumor microenvironment (“TME”). This CD36-mediated adaption not only alters metabolic regulations but also impacts the immune cell properties to construct an immunosuppressive TME with increased exhausted tumor-reactive CD8+ T cells and immunosuppressive regulatory T cells.

PLT012, a humanized anti-CD36 antibody, was developed to block CD36-mediated fatty acid uptake without interfering with other physiological functions. PLT012 aims to disarm intratumoral Treg and boost tumor-reactive CD8+ T cells in the tumor microenvironment, leading to remarkable anti-tumor efficacy and synergistic effects with current ICB therapies. More detailed data will be presented at SITC 2023.

‍